NCT03397186View on ClinicalTrials.gov

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 19, 2018

Primary Completion Date

January 1, 2021

Study Completion Date

May 1, 2021

Conditions
Myxoid LiposarcomaRound Cell LiposarcomaStage III Soft Tissue Sarcoma AJCC v7Stage IV Soft Tissue Sarcoma AJCC v7Metastatic Soft Tissue SarcomaUnresectable Soft Tissue Sarcoma
Interventions
PROCEDURE

Biopsy

Undergo biopsy

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Trabectedin

Given as standard of care

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER

NCT03397186 - Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | Biotech Hunter | Biotech Hunter